|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3557-3560.
Prepublished online as a Blood First Edition Paper on August 9, 2007; DOI 10.1182/blood-2006-08-036947.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Brief Report
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Paul G. Richardson1,
Pieter Sonneveld2,
Michael Schuster3,
David Irwin4,
Edward Stadtmauer5,
Thierry Facon6,
Jean-Luc Harousseau7,
Dina Ben-Yehuda8,
Sagar Lonial9,
Hartmut Goldschmidt10,
Donna Reece11,
Jesus San Miguel12,
Joan Bladé13,
Mario Boccadoro14,
Jamie Cavenagh15,
Melissa Alsina16,
S. Vincent Rajkumar17,
Martha Lacy17,
Andrzej Jakubowiak18,
William Dalton16,
Anthony Boral19,
Dixie-Lee Esseltine19,
David Schenkein20, and
Kenneth C. Anderson1
1 Dana-Farber Cancer Institute, Boston, MA;
2 University Hospital Rotterdam, Rotterdam, The Netherlands;
3 New York-Presbyterian Hospital, New York City;
4 Alta Bates Cancer Center, Berkeley, CA;
5 University of Pennsylvania Cancer Center, Philadelphia;
6 Hospital Claude Huriez, Lille, France;
7 Hotel Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France;
8 Hadassah University Hospital, Jerusalem, Israel;
9 Emory University, Atlanta, GA;
10 University of Heidelberg, Heidelberg, Germany;
11 Princess Margaret Hospital, Toronto, ON;
12 Hospital University of Salamanca, Salamanca, Spain;
13 University of Barcelona, Barcelona, Spain;
14 University of Torino, Torino, Italy;
15 St Bartholomew's Hospital, London, United Kingdom;
16 H. Lee Moffitt Cancer Center, Tampa, FL;
17 Mayo Clinic, Rochester, MN;
18 University of Michigan Comprehensive Cancer Center, Ann Arbor;
19 Millennium Pharmaceuticals, Cambridge, MA; and
20 Genentech, San Francisco, CA
 |
Abstract
|
|---|
Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230
[ClinicalTrials.gov]
).
|
Introduction
|
|---|
The international, randomized, phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial led to full approval of bortezomib in 2005 for treatment of multiple myeloma (MM) patients who have received at least one prior therapy. In the initial APEX report, single-agent bortezomib demonstrated superior efficacy to high-dose dexamethasone in terms of significantly longer median time to progression (TTP, 6.2 vs 3.5 months, P < .001), higher response rates (38% vs 18%, P < .001), and improved survival (1-year survival rate: 80% vs 66%, P = .003; hazard ratio for overall survival [OS]: 0.57, P = .001).1
As a result, the high-dose dexamethasone arm was halted at interim analysis following the recommendations of an independent data-monitoring committee. A companion crossover study, which offered single-agent bortezomib initially only to patients with progressive disease (PD) on high-dose dexamethasone, was opened to all patients randomized to high-dose dexamethasone.
In this updated analysis, we report whether bortezomib continues to provide improved survival compared with high-dose dexamethasone. Other updated efficacy parameters for the bortezomib arm are reported. The relationship between duration of response (DOR) and quality of response as measured by M-protein reduction was analyzed, as was the relationship between DOR and time to first response (TTR). In addition, we report an exploratory analysis comparing patients who initially received bortezomib on APEX with those who first received high-dose dexamethasone and crossed over to receive bortezomib on the companion study.
|
Methods
|
|---|
Approval was obtained from the institutional review boards of all participating institutions (Document S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). Informed consent was obtained in accordance with the Declaration of Helsinki. APEX study details have been reported.1 Patients with MM and measurable disease following 1 to 3 prior therapies were randomized to receive bortezomib (Millennium Pharmaceuticals [Cambridge, MA] and Johnson & Johnson Pharmaceuticals Research & Development [Raritan, NJ]), 1.3 mg/m2 on days 1, 4, 8, and 11 for eight 3-week cycles, then on days 1, 8, 15, and 22 for three 5-week maintenance cycles, or dexamethasone 40 mg on days 1 to 4, 9 to 12, and 17 to 20 for four 5-week cycles, then days 1 to 4 for five 4-week cycles. Patients were assessed for disease status and survival every 3 weeks for 39 weeks. Follow-up occurred every 6 weeks until PD, then every 3 months for survival. Patients on the companion crossover study received single-agent bortezomib as administered according to the dose and schedule of the bortezomib treatment arm of the APEX study.
Updated analyses of survival of patients originally randomized to bortezomib and dexamethasone were performed. Updated efficacy analyses were performed for all 333 patients in the bortezomib arm, following treatment completion in 85 patients still receiving bortezomib at initial analysis (the dexamethasone arm was halted; additional analysis was not possible). These analyses included response rate (European Blood and Bone Marrow Transplant Group [EBMT] criteria),2 TTP, TTR, DOR, and best M-protein reduction (a key component of EBMT criteria) as measures of response quality. Response and survival with single-agent bortezomib were compared between patients who crossed over to bortezomib after PD on dexamethasone and patients initially randomized to bortezomib. Patients in this analysis were matched for age (< 65 years or  65 years), prior thalidomide, baseline albumin (< 35 g/L [3.5 g/dL] or 35 g/L [3.5 g/dL]), and number of therapies prior to APEX enrollment.
|
Results and discussion
|
|---|
Patients' baseline characteristics have been described.1 Median length of bortezomib therapy in this updated analysis was 6 cycles, as in initial analysis; 39% of patients completed the planned 8 cycles compared with 29% in the initial analysis.
Median follow-up was 22 months in surviving patients (44% of patients have died), an additional 14 months of follow-up compared with the initial analysis. Median OS was 29.8 months (95% CI: 23.2–not evaluable) in the bortezomib arm versus 23.7 months (95% CI: 18.7-29.1) in the dexamethasone arm (hazard ratio = .77, P = .027), despite more than 62% of dexamethasone patients crossing over to receive bortezomib (Figure 1A). The 1-year survival rates were 80% and 67%, respectively (P = .001). These results show that, with longer follow-up and despite substantial crossover from the high-dose dexamethasone arm, bortezomib continues to demonstrate improved survival compared with dexamethasone. Figure 1A also shows survival for a subset of dexamethasone patients who crossed over to bortezomib after PD within 6 months. Because baseline characteristics are not matched with bortezomib patients, the exploratory analysis was conducted to compare earlier versus later bortezomib.
View larger version (37K):
[in this window]
[in a new window]
|
Figure 1. Bortezomib continues to demonstrate improved survival compared with high-dose dexamethasone, and overall quality of response continues to improve with longer bortezomib treatment beyond initial response. (A) Updated overall survival in the bortezomib (n = 333) and high-dose dexamethasone (n = 336) arms, plus overall survival in the subset of dexamethasone patients who crossed over to receive bortezomib following PD within 6 months of study start (n = 113); the baseline characteristics of these poorer-prognosis patients are not matched with those of patients on the bortezomib arm. (B) Time to maximal serum M-protein reduction plus time to first evidence ( 25% serum M-protein reduction) of response in patients responding to bortezomib in whom baseline serum M-protein data were available (n = 111 of 135 responders), as a proportion of all patients randomized to bortezomib.
|
|
Overall response rate (complete response [CR] + partial response [PR]) in the bortezomib arm improved from 38% at initial analysis to 43%; CR rate improved from 6% to 9%; median TTP, TTR, and DOR remained unchanged (Table 1). Median DOR was longer in patients achieving 100% M-protein reduction (n = 40, 11.5 months) compared with patients achieving 50% or more but less than 100% reduction (n = 71, 7.6 months). Notably, DOR was not associated with TTR; rapid achievement of first response did not predict longer DOR (r = .03), suggesting comparable clinical benefit irrespective of time taken to respond.
View this table:
[in this window]
[in a new window]
|
Table 1. Median time to progression, response rate, median time to first response, and median duration of response in patients on the bortezomib arm in this updated analysis versus the initial analysis of bortezomib and high-dose dexamethasone
|
|
Among 135 patients responding to bortezomib, 73 (54%) achieved their first response (CR, PR, or minor response [MR]) after treatment cycle 2. First response was achieved on or after cycle 4 in 39 (29%) patients, and on or after cycle 6 in 10 (7%) patients. In total, 76 (56%) patients had improved response after first response; 20 (15%) improved from MR or PR to CR, and 56 (41%) from MR to PR. Best response was achieved in cycle 1 or 2 in 47 (35%) patients. When best response was CR, it occurred on or after cycle 8 in 22% of patients. Similarly, approximately 20% of patients who responded achieved maximal M-protein reduction in cycle 8 or later (Figure 1B). Therefore, longer therapy beyond rapid initial responses led to continued improvement in overall quality of response. This, combined with the finding that higher quality of response was associated with longer duration of response, supports extended treatment with bortezomib beyond initial response in patients tolerating therapy.
Where they occurred, only slight differences were seen in incidences of commonly reported adverse events between updated and initial analyses.1 Optimal duration of therapy is determined by the risk-benefit ratio of continuing treatment. No new safety concerns were identified in this updated analysis compared with the initial report1 or 2 phase 2 trials of bortezomib in relapsed and/or refractory MM.3–5 In addition, data from an extension study6 of the phase 2 trials3,4 indicate that prolonged therapy is associated with a manageable safety profile, and no evidence of new, cumulative toxicity.6
In the exploratory analysis of 118 matched pairs of patients receiving bortezomib earlier (on APEX) compared with later (on companion study following PD on high-dose dexamethasone), median OS was 23.2 months (95% CI: 20.1–not evaluable) versus 16.3 months (95% CI: 14.5–not evaluable; hazard ratio = .67, P = .047), respectively; one-year survival probability was 75% versus 65% (P = .095). Response rate (CR + PR) was 44% versus 34% (P = .153). The longer survival seen in patients receiving bortezomib earlier, together with data from additional APEX analyses showing greater efficacy with bortezomib at first relapse versus later salvage therapy,1,7,8 indicates that, as might be expected, earlier use of bortezomib in relapsed MM may offer greater benefit. Bortezomib-based combinations are also being investigated with the aim of improving outcomes, with promising results to date.9–24
In conclusion, bortezomib continues to demonstrate superior survival to high-dose dexamethasone in patients with relapsed MM following 1 to 3 prior therapies, confirming the substantial activity of bortezomib as a single agent and further supporting its study both earlier in the disease course and in combination regimens.
|
Authorship
|
|---|
Contribution: A.B., J.B., D.S., J.S.M., P.G.R., S.V.R., D.-L.E., K.C.A., and W.D. were involved in conception and design of the study; J.C., A.B., D.B.-Y., M.A., H.G., P.G.R., D.R., M.B., A.J., J.-L.H., D.I., E.S., K.C.A., S.L., T.F., and M.S. performed the research; J.C., J.B., M.A., H.G., J.S.M., P.G.R., D.R., M.L., A.J., D.I., K.C.A., and M.S. collected data; A.B., P.S., D.S., P.G.R., D.-L.E., K.C.A., W.D., and M.S. were involved in data analysis; P.G.R., D.-L.E., and K.C.A. were involved in writing the paper; J.C., J.B., D.B.-Y., P.S., J.S.M., P.G.R., D.R., S.V.R., J.-L.H., D.-L.E., D.I. E.S., K.C.A., S.L., M.B., and M.S. reviewed and gave final approval of the paper.
Conflict-of-interest disclosure: A.B. and D.S. have declared a financial interest in Millennium Pharmaceuticals, whose product was studied in the present work. A.B., D.S., and D.-L.E. are employed by Millennium Pharmaceuticals, whose product was studied in the present work. D.R., S.V.R., J.-L.H., M.S., and K.A. have received research funding from Millennium Pharmaceuticals. E.S. has received research funding from Celgene.
Correspondence: Paul G. Richardson, Dana-Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115; e-mail:paul_richardson{at}dfci.harvard.edu.
|
Acknowledgments
|
|---|
This work was supported in part by Millennium Pharmaceuticals and Johnson & Johnson Pharmaceuticals Research & Development.
The study investigators thank the patients for their participation in this trial, as well as the study nurses and clinical research associates for their important contributions to the implementation and management of the study. A complete list of the APEX Investigators may be found in Document S2.
|
Footnotes
|
|---|
Submitted August 2, 2006;
accepted June 20, 2007.
Prepublished online as Blood First Edition Paper, August 9, 2007
DOI: 10.1182/blood-2006-08-036947
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
|
References
|
|---|
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487–2498.[Abstract/Free Full Text]
- Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115–1123.[CrossRef][Medline]
[Order article via Infotrieve]
- Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609–2617.[Abstract/Free Full Text]
- Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165–172.[CrossRef][Medline]
[Order article via Infotrieve]
- Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777–3784.[Abstract/Free Full Text]
- Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141–2148.[CrossRef][Medline]
[Order article via Infotrieve]
- Sonneveld P, Richardson PG, Schuster MW, et al. Bortezomib at first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma [abstract]. Haematologica 2005; 90:146–147 Abstract P140.721.[Medline]
[Order article via Infotrieve]
- Vogl DT, Stadtmauer EA, Richardson PG, et al. Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial [abstract]. J Clin Oncol 2006; 23:433s Abstract 7546.
- Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91:929–934.[Abstract/Free Full Text]
- Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29:587–590.[CrossRef][Medline]
[Order article via Infotrieve]
- Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [abstract]. Blood 2005; 106:716a Abstract 2549.
- Reece DE, Piza GR, Trudel S, et al. A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma [abstract]. Blood 2006; 108:1009a Abstract 3536.
- Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001–37: superior outcome in patients with normal cytogenetics and no prior T [abstract]. Blood 2005; 106:717a Abstract 2552.[CrossRef]
- Teoh G, Tan D, Hwang W, et al. Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed/refractory multiple myeloma [abstract]. J Clin Oncol 2006; 24:683s Abstract 17537.
- Richardson PG, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood 2006; 108:124a Abstract 405.
- Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058–3065.[Abstract/Free Full Text]
- Hollmig K, Stover J, Talamo G, et al. Bortezomib (VelcadeTM) + adriamycinTM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM) [abstract]. Blood 2004; 104:659a Abstract 2399.[CrossRef]
- Chanan-Khan AA, Padmanabhan S, Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma [abstract]. Blood 2006; 108:1010a Abstract 3539.
- Friedman J, Al-Zoubi A, Kaminski M, Kendall T, Jakubowiak A. A new model predicting at least a very good partial response in patients with multiple myeloma after 2 cycles of Velcade-based therapy [abstract]. Haematologica 2006; 91:273 Abstract P.0741.
- Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937–944.[Abstract/Free Full Text]
- Popat R, Williams C, Cook M, et al. A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma [abstract]. Blood 2006; 108:1011a Abstract 3542.
- Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109:2767–2772.[Abstract/Free Full Text]
- Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1
 and angiogenic cytokines [abstract]. Blood 2006; 108:1010a–1011a Abstract 3541.
- Richardson P, Chanan-Khan AA, Lonial S, et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM) [abstract]. Blood 2006; 108:124a–125a Abstract 406.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Blood,
August 20, 2009;
114(8):
1489 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Richardson, S. Jagannath, M. Hussein, J. Berenson, S. Singhal, D. Irwin, S. F. Williams, W. Bensinger, A. Z. Badros, R. Vescio, et al.
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Blood,
July 23, 2009;
114(4):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, W. Xie, C. Mitsiades, A. A. Chanan-Khan, S. Lonial, H. Hassoun, D. E. Avigan, A. L. Oaklander, D. J. Kuter, P. Y. Wen, et al.
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
J. Clin. Oncol.,
July 20, 2009;
27(21):
3518 - 3525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-M. Yang, D. Barbone, D. A. Fennell, and V. C. Broaddus
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids
Am. J. Respir. Cell Mol. Biol.,
July 1, 2009;
41(1):
14 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Loeffler-Ragg, D. Mueller, G. Gamerith, T. Auer, S. Skvortsov, B. Sarg, I. Skvortsova, K. J. Schmitz, H.-J. Martin, J. Krugmann, et al.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib
Mol. Cancer Ther.,
July 1, 2009;
8(7):
1995 - 2006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kuhn, S. A. Hunsucker, Q. Chen, P. M. Voorhees, M. Orlowski, and R. Z. Orlowski
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Blood,
May 7, 2009;
113(19):
4667 - 4676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Knop, C. Gerecke, P. Liebisch, M. S. Topp, U. Platzbecker, O. Sezer, C. Vollmuth, K. Falk, A. Glasmacher, U. Maeder, et al.
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Blood,
April 30, 2009;
113(18):
4137 - 4143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bianchi, L. Oliva, P. Cascio, N. Pengo, F. Fontana, F. Cerruti, A. Orsi, E. Pasqualetto, A. Mezghrani, V. Calbi, et al.
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Blood,
March 26, 2009;
113(13):
3040 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade and L. Rosinol
Changing paradigms in the treatment of multiple myeloma
Haematologica,
February 1, 2009;
94(2):
163 - 166.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Berenson, O. Yellin, R. Patel, H. Duvivier, Y. Nassir, R. Mapes, C. D. Abaya, and R. A. Swift
A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Clin. Cancer Res.,
February 1, 2009;
15(3):
1069 - 1075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Brenner, A. Gondos, and D. Pulte
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Haematologica,
February 1, 2009;
94(2):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, C. Mitsiades, J. Laubach, D. Chauhan, T. Hideshima, and K. Anderson
Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors
ASCO Educational Book,
January 1, 2009;
2009(1):
163 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreau, V. Coiteux, C. Hulin, X. Leleu, H. van de Velde, M. Acharya, and J.-L. Harousseau
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
Haematologica,
December 1, 2008;
93(12):
1908 - 1911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chanan-Khan, P. Sonneveld, M. W. Schuster, E. A. Stadtmauer, T. Facon, J.-L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, et al.
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
J. Clin. Oncol.,
October 10, 2008;
26(29):
4784 - 4790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al.
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N. Engl. J. Med.,
August 28, 2008;
359(9):
906 - 917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res.,
March 15, 2008;
14(6):
1649 - 1657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Top
Abstract
Introduction